Impact Investing in Healthcare

During the past several years, the somewhat overlapping concepts of Impact Investing and Environmental, Social and Governance (ESG) are increasingly top of mind for everyday investors. Impact Investing refers to...

Future Forward: Health Innovators Launch Inventions Prompted by the Pandemic

Solaris Vaccines' Chief Scientific Officer, Raymond Goodrich, featured in CBSA article “Future Forward: Health Innovators Launch Inventions Prompted by the Pandemic." Click here to download the article.

VIC Fellows Spotlight: Secondra Holmes, PhD

The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovation from global sources. We are pleased to highlight the...

Neurexis Therapeutics Awarded NIH Phase I SBIR Grant to Accelerate IND-Enabling Studies of Neuroprotective Therapeutic

A promising approach for preventing cognitive and behavioral impairment following ischemic events such as cardiac arrest and stroke. Aurora, CO - Neurexis Therapeutics, Incorporated, announces it has been awarded a...

Nob Hill Therapeutics Selected as a Finalist for RESI Innovator’s Pitch Challenge

Nob Hill Therapeutics was selected as a finalist in the Redefining Early Stage Investments (RESI) Innovator’s Pitch Challenge (IPC). An opportunity for early-stage companies to gain exposure to conference attendees,...

CardioWise Named Quarterfinalists at the UCSF Health Awards

The University of California San Francisco (UCSF) Health Awards has selected CardioWise, Inc. as a Quarterfinalist in the Hospital Diagnostics Category. The awards showcase the health tech industry, showcasing the best...

University Technology Licensing Part 2: Assessing the Opportunities and Negotiating Licenses

Part 2: Technology Transfer and License Terms As was described in Part I of this article [1], VIC has a systematic and thorough technology assessment process. We also have extensive experience negotiating licenses for...

Solaris Vaccines Formed to Develop and Commercialize a Rapid, Flexible Vaccine Manufacturing Platform

New company advances novel vaccines to better fight COVID-19 and other pathogens FORT COLLINS, CO - VIC Technology Venture Development, LLC (VIC), announced today the formation of Colorado-based Solaris Vaccines, Inc.,...

VIC Fellows Spotlight: Evan Goldberg, PhD

The VIC Fellows Program provides an opportunity for individuals with relevant expertise and interest to learn how to identify and evaluate promising innovation from global sources. We are pleased to highlight the...

University Technology Licensing: Assessing the Opportunities and Negotiating Licenses

Part 1: Opportunity Sourcing and Assessment The U.S. invests more than $120 billion in federally sponsored research funding at universities and national labs. Technology Transfer Offices (TTOs) are unique entities...

FEATURED RESOURCES

Insight
Zero Federal Capital Gains Taxes on High-Return Investments
White Paper
Portfolio Diversification in Times of Market Volatility
Insight
Protecting Early Investors in Capital-Intensive Life Science Companies
Interview
Inside Blackstone LaunchPad at UT Southwestern Medical Center with Brad Phelan
White Paper
University Technology Licensing: Assessing the Opportunities and Negotiating Licenses
Updates
VIC 2021 Mid-Year Update Executive Summary
News
Solaris Vaccines Formed to Develop and Commercialize a Rapid, Flexible Vaccine Manufacturing Platform
Interview
VIC Fellows Spotlight: Evan Goldberg, PhD
From The Corner Office
SFC Fluidics Nears FDA Submission